Daniel J. OConnor appointed President, CEO of Advaxis, Inc.
August 22, 2013
Advaxis, Inc. announced the appointment of Daniel J. O’Connor ’95 as president and chief executive officer. In assuming the role, O’Connor also becomes a member of the company’s board of directors.
Advaxis describes itself as a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases.
“I am very pleased to be appointed to lead Advaxis at this pivotal point in its drug development and commercialization efforts, and I am prepared for this challenge,” remarked O’Connor, also noting that the company’s “innovative science and IP hold great promise for addressing many important areas of unmet medical needs.”
O’Connor’s list of accomplishments includes over fifteen years of executive experience in the biopharmaceutical industry. He previously served as senior vice president of ImClone Systems. In that capacity, Advaxis notes he played a key role in resolving numerous issues facing the company and closed several important deals leading to its sale to Eli Lilly in 2008.